Lunai Bioworks has triggered alarm among shareholders by announcing a substantial reverse stock split at a ratio of 1-for-10. Fundamental Challenges PersistThe timing of this reverse split raises significant questions, as Lunai Bioworks shares recently traded at just $0.17—a clear reflection of the company's ongoing operational difficulties. By executing this reverse split, Lunai Bioworks aims to surmount these regulatory hurdles and potentially attract institutional investors who typically avoid penny stock investments. Investor Implications and Future ProspectsThe critical consideration for market participants remains whether a reverse stock split can resolve underlying business challenges. Without demonstrable clinical progress and with therapeutic candidates remaining in preclinical phases, any stock price appreciation may prove temporary.